Phase 2 Trial Tests Nivolumab Plus Ipilimumab Scheduling in Metastatic Kidney Cancer

Metastatic renal cell carcinoma is one of the cancers most responsive to modern immunotherapy, yet significant questions remain about how to optimize treatment regimens. Checkpoint inhibitors targeting PD-1 and CTLA-4 have individually demonstrated activity, and their combination has become a standard-of-care option — but the ideal scheduling and sequencing of these agents is still being worked out in clinical practice.

This completed phase 2 trial, sponsored by the Swiss Cancer Institute, enrolled 74 patients with metastatic renal cell carcinoma to directly address that gap. The primary objective was to determine the efficacy of the combination of nivolumab (anti-PD-1) and ipilimumab (anti-CTLA-4) under a defined dosing schedule. The trial ran from December 2017 to April 2025, allowing for meaningful follow-up data across a sizable patient cohort.

A particularly interesting aspect of the study design was its expansion phase, which examined a nuanced clinical scenario: whether ipilimumab could play a meaningful role when patients experience clinically insignificant progression on nivolumab. This addresses a real-world dilemma oncologists face — when to escalate therapy versus continue monitoring in patients with early or minor radiographic changes.

The findings carry potential implications for how dual checkpoint blockade is used in routine oncology care. If a specific schedule proves superior, or if ipilimumab reliably rescues partial non-responders, this could refine treatment algorithms and reduce unnecessary toxicity from premature combination dosing.

However, several important caveats apply. This summary is based on the trial registration abstract only — full efficacy and safety data have not been reviewed here. With 74 patients in a phase 2 design, the study is not powered for definitive conclusions, and broader validation in phase 3 trials would be needed before practice-changing recommendations can be made.